Introduction

This analysis focuses on the changing landscape of the commercial environment in the global arthritis market and investigates key strategies required to succeed. Analysis of company portfolio strategies and product positioning provides in-depth knowledge of how specific company strategies result in varying levels of commercial returns. 

Scope

Detailed case studies featuring company portfolio, product development and launch strategies of leading global players in arthritis 

Global sales data for the major classes used in treating arthritis - NSAIDs, DMARDs, HA viscosupplements and steroids 

Event-based forecasts to 2011 for the top selling drugs in each class 

SWOT analyses of key arthritis drugs, along with 12-month event screens - providing detailed knowledge of events specific to each product 

Report Highlights

Despite facing adversity in the past year, including continued negative publicity surrounding the cardiovascular side effect profile of Vioxx and the delayed launch of Arcoxia, Merck will remain a strong competitor for Pfizer/Pharmacia in the future and the COX-II inhibitor class will continue to flourish through 2011. 

The alleviation of Enbrel’s supply shortage through the new manufacturing facility approved in early 2003 will enable Amgen to regain a significant portion of sales lost to J&J’s Remicade although Humira is presenting formidable competition for both drugs. 

Reasons to Purchase

Target current and future growth areas through identification of the strongest product lifecycle and pricing strategies 

Learn from case studies analyzing details of the most successful drug launches in the arthritis market 

Plan future product positioning through utilization of event-based forecasts for all major arthritis drugs 

Publisher: Datamonitor Immune Disorders and Inflammation Rep. 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor_Immune_Disorders_and_Inflammation.html#a184